The Motley Fool

I’d buy GlaxoSmithKline and AstraZeneca given this huge AI breakthrough

Image source: Getty Images

On 30 November, Alphabet’s London-based artificial intelligence company, DeepMind, announced a huge breakthrough. Given a sequence of amino acids, DeepMind’s AI solution can reliably and rapidly predict the shape of a protein to within approximately the distance of an atom, around two-thirds of the time. In most of the remaining cases, the AI solution is highly accurate too. 

By knowing the shape of a protein, scientists can better predict interactions. Many industry experts have said the breakthrough is a game changer. They believe the breakthrough could expedite the discoveries of new drugs in the future. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Given the game changing aspect of the discovery, here’s what I think it means for GlaxoSmithKline (LSE:GSK) and AstraZeneca (LSE:AZN)

The market reaction to the news

Shares of GSK and AZN barely moved on the news, although it was widely regarded as a breakthrough. From 27 November to 2 December, AZN rallied about 1.5% on the NYSE. GSK rallied around 1%. I think the market reaction was muted because the breakthrough won’t make new blockbuster product discoveries possible right away. 

Given that many investors care only about the short term, the breakthrough doesn’t matter much in their holding timelines. It doesn’t change the value of GSK or AZN that much in those investors’ eyes. 

Why I’d buy AstraZeneca and GlaxoSmithKline

The breakthrough might not meaningfully affect industry earnings right away, but it will certainly be positive in the long run. The New York Times explains the breakthrough’s potential impact: If DeepMind’s methods can be refined, [..] they could speed the development of new drugs as well as efforts to apply existing medications to new viruses and diseases”.

In particular, the DeepMind AI breakthrough could help scientists in their quest to find eventual drug solutions to major illnesses such as Alzheimer’s. The AI method could also help accelerate pharmaceutical/vaccine responses to future pandemics. 

Both GlaxoSmithKline and AstraZeneca have tried to solve Alzheimer’s in the past. I think the breakthrough could help them if the companies choose to continue to tackle the problem. The Alzheimer’s market is huge, and a drug that could help defeat Alzheimer’s would be in high demand in my view.

I think another reason to be bullish on GlaxoSmithKline and AstraZeneca is that the breakthrough indicates how quickly technology is advancing. 

Before the breakthrough, many thought that a solution to this problem was years to decades away. The solution, albeit still crude, fortunately was made just recently. If technology is advancing faster than expected, I believe the market is underpricing the potential impact of new pharmaceutical discoveries that Big Pharma can make. Were Big Pharma to come up with solutions faster than estimates because technology is advancing faster, I think the industry’s overall profits could also be higher than current expectations. 

If that were to happen, I think GSK and AZN could both benefit given their leading positions in the industry. To me, both are undervalued and GSK has an attractive dividendGiven the two companies’ future potential, I’d buy and hold both stocks for the long term. 

A Top Share with Enormous Growth Potential

Savvy investors like you won’t want to miss out on this timely opportunity…

Here’s your chance to discover exactly what has got our Motley Fool UK analyst all fired up about this ‘pure-play’ online business (yes, despite the pandemic!).

Not only does this company enjoy a dominant market-leading position…

But its capital-light, highly scalable business model has previously helped it deliver consistently high sales, astounding near-70% margins, and rising shareholder returns … in fact, in 2019 it returned a whopping £150m+ to shareholders in dividends and buybacks!

And here’s the really exciting part…

While COVID-19 may have thrown the company a curveball, management have acted swiftly to ensure this business is as well placed as it can be to ride out the current period of uncertainty… in fact, our analyst believes it should come roaring back to life, just as soon as normal economic activity resumes.

That’s why we think now could be the perfect time for you to start building your own stake in this exceptional business – especially given the shares look to be trading on a fairly undemanding valuation for the year to March 2021.

Click here to claim your copy of this special report now — and we’ll tell you the name of this Top Growth Share… free of charge!

Jay Yao has no position in any of the shares mentioned. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. The Motley Fool UK owns shares of and has recommended Alphabet (C shares). The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.